NEWTON, Mass., Aug. 3, 2021 /PRNewswire/ -- Karyopharm
Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical
company pioneering novel cancer therapies, today announced that
Richard Paulson, President and Chief
Executive Officer, will participate on a speaker panel at the 2021
Wedbush PacGrow Healthcare Virtual Conference titled, "Building
Back a Better Commercial Infrastructure – Selling in COVID Times"
and participate in a fireside chat at the Canaccord Genuity
41st Annual Growth Conference. Details regarding these
upcoming virtual investor conferences are below.
2021 Wedbush PacGrow Healthcare Virtual
Conference
Date: Tuesday, August 10,
2021
Time: 8:35 AM Eastern Time
Canaccord Genuity 41st Annual Growth
Conference
Date: Thursday, August 12,
2021
Time: 3:30 PM Eastern Time
A live webcast of the panel and fireside chat can be accessed
under "Events & Presentations" in the Investor section of
the Company's
website, http://investors.karyopharm.com/events-presentations.
A replay of the webcasts will be archived on the Company's website
for 30 days following the panel and fireside chat.
About Karyopharm Therapeutics
Karyopharm Therapeutics Inc. (NASDAQ: KPTI) is a
commercial-stage pharmaceutical company pioneering novel cancer
therapies and dedicated to the discovery, development, and
commercialization of first-in-class drugs directed against nuclear
export for the treatment of cancer and other diseases. Karyopharm's
Selective Inhibitor of Nuclear Export (SINE) compounds function by
binding with and inhibiting the nuclear export protein XPO1 (or
CRM1). Karyopharm's lead compound, XPOVIO® (selinexor), is approved
in the U.S. in multiple hematologic malignancy indications,
including in combination with Velcade® (bortezomib) and
dexamethasone for the treatment of adult patients with multiple
myeloma after at least one prior therapy, in combination with
dexamethasone for the treatment of adult patients with heavily
pretreated multiple myeloma and as a monotherapy for the treatment
of adult patients with relapsed or refractory diffuse large B-cell
lymphoma. NEXPOVIO® (selinexor) has also been granted conditional
marketing authorization in combination with dexamethasone for adult
patients with heavily pretreated multiple myeloma by the European
Commission. In addition to single-agent and combination activity
against a variety of human cancers, SINE compounds have also shown
biological activity in models of neurodegeneration, inflammation,
autoimmune disease, certain viruses and wound-healing. Karyopharm
has several investigational programs in clinical or preclinical
development. For more information, please visit
www.karyopharm.com.
View original
content:https://www.prnewswire.com/news-releases/karyopharm-announces-upcoming-virtual-investor-conference-participation-301346572.html
SOURCE Karyopharm Therapeutics Inc.